Young Choi, MD
Cards
About
Titles
Professor Emeritus of Pathology
Director, Bridgeport Hospital Clinical LaboratoriesBiography
I have developed and provided a full aspects of pathology and lab medicine at the Bridgeport Hospital for the last 17 years. I have contributed a quality of patient care in the community. I will continue to pursue my career in pathology and lab medicine and continue my research interest.
Appointments
Pathology
EmeritusPrimary
Other Departments & Organizations
Education & Training
- Resident
- State University of New York (1972)
- Resident
- Boston City Hospital - Mallory Institute of Pathology (1970)
- Fellow
- Memorial Sloan Kettering Cancer Center (1969)
- Resident
- New York Hospital-Cornell Medical College (1968)
- MD
- Seoul National University (1966)
Board Certifications
Cytopathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 1991
Immunopathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 1984
Anatamic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 1972
Research
Overview
Currently, ERa is the main therapeutic and prognostic marker for breast cancer but about 30% do not respond to the antiestrogens. Some studies have shown that ERb isoforms are predictive marker to antiestrogens. ERb isoforms also are significantly expressed in ERa negative tumors. Thus, ERb may be the potential targeted therapy in some ERa and ERa negative breast cancers. ERb isoforms mRNA by qPCR and protein expression by immunohistochemistry will be tested in both ERa positive and ERa negative breast cancer tissues, and also breast cancer cell lines (BCC). Then BCC will be subjected to estrogens and different antiestrogens to determine their responses, and their effects and analyzed for their potential therapeutic effects. We hypothesize that ERß will eventually play an important role in controlling growth of breast cancers. We believe that ERb isoforms may be new potential therapeutic targets to the patients with non-responder to the current available ERa targeted antiestrogen therapy, and also ERa negative breast cancers who have not received the benefit of the current antiestrogen therapy.
Medical Subject Headings (MeSH)
Breast Neoplasms; Estrogen Receptor alpha; Medical Laboratory Science; Pathology; Selective Estrogen Receptor Modulators